000			01796 a2200517 4500
005			20250516081703.0
264		0	_c20120612
008			201206s 0 0 eng d
022			_a0391-1977
040			_aNLM _beng _cNLM
100	1		_aDe Francia, S
245	0	0	_aMitotane treatment for adrenocortical carcinoma: an overview. _h[electronic resource]
260			_bMinerva endocrinologica _cMar 2012
300			_a9-23 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aATP Binding Cassette Transporter, Subfamily B
650	0	4	_aATP Binding Cassette Transporter, Subfamily B, Member 1 _xantagonists & inhibitors
650	0	4	_aAdrenal Cortex Neoplasms _xdiagnosis
650	0	4	_aAdrenal Insufficiency _xchemically induced
650	0	4	_aAdrenalectomy
650	0	4	_aAntineoplastic Agents, Hormonal _xadverse effects
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aBiotransformation
650	0	4	_aCarcinoma _xdiagnosis
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aClinical Trials as Topic
650	0	4	_aDelayed Diagnosis
650	0	4	_aDrug Resistance, Neoplasm _xdrug effects
650	0	4	_aFemale
650	0	4	_aGastrointestinal Diseases _xchemically induced
650	0	4	_aHumans
650	0	4	_aIncidental Findings
650	0	4	_aMale
650	0	4	_aMitotane _xadministration & dosage
650	0	4	_aMolecular Structure
650	0	4	_aNeoplasm Proteins _xantagonists & inhibitors
650	0	4	_aProdrugs _xpharmacokinetics
650	0	4	_aTreatment Outcome
700	1		_aArdito, A
700	1		_aDaffara, F
700	1		_aZaggia, B
700	1		_aGermano, A
700	1		_aBerruti, A
700	1		_aDi Carlo, F
773	0		_tMinerva endocrinologica _gvol. 37 _gno. 1 _gp. 9-23
999			_c21589811 _d21589811